出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2023年4月
移植診断市場 : 技術（PCR、NGS、サンガーシーケンシング）、製品（機器、試薬、ソフトウェア）、用途（HLA、血液プロファイル、病原体検出）、タイプ（心臓、腎臓、肝臓、骨髄）、エンドユーザーと地域別 – 2028年までの世界予測
Transplant Diagnostics Market by Technology (PCR, NGS, Sanger Sequencing), Product (Instrument, Reagent, Software), Application (HLA, Blood Profile, Pathogen Detection), Type (Heart, Kidney, Liver, Bone Marrow), End User & Region – Global Forecast to 2028
| ページ数 | 254 |
| 図表数 | 212 |
| 種別 | 英文調査報告書 |
| 価格 |
The transplant diagnostic market is projected to reach USD 6.8 billion by 2028 from USD 4.4 billion in 2022, at a CAGR of 7.4% during the forecast period. For many patients with chronic dialysis-dependent end-stage renal disease, transplantation is one of their top treatment choices. Additionally, cases involving the heart, liver, and bone marrow can be treated with transplantation. Additionally, over the past ten years, companies have made significant strides in developing better HLA typing technologies, antibody monitoring, tools, and software. This is gradually being used for diagnostic purposes when transplanting various body organs. These are the factors contributing to increasing transplant diagnostic market.
“The Kidney transplants to hold the largest share of the market in 2022”
According to transplant type, the kidney transplant holds the largest market share in 2022. Due to longer lifespans and rising rates of obesity, diabetes, and hypertension, chronic kidney disease is becoming more prevalent and there are more patients needing hemodialysis.These factors are causing an increase in the market share for kidney transplants.
“The Molecular based assay technology is holding the largest share of the market in 2022”
Based on technology, the molecular-based assay technology market is classified into PCR-based Molecular assays and Sequencing based molecular assays. The PCR-based molecular assays hold a larger share than sequencing-based assays like sanger sequencing and NGS sequencing.
“The market in North America region is expected to witness the highest growth during the forecast period.”
North America accounted for the largest market share—45.5%—in 2022. The increasing private -public funding and increasing public awareness for organ donation is contributing to the high number of the share of North America.
While APAC is expected to witness significant growth in the coming years. The transplant diagnostic market in the APAC region is expected to register a CAGR of 8.3% during the forecast period, primarily due to the growing number of hospitals in Asian countries and favorable government initiatives.
A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–40%, Tier 2–30%, and Tier 3– 30%
• By Designation: C-level–27%, Director-level–18and Others–55%
• By Region: North America–45%, Europe–15%, Asia Pacific–20%, Latin America–15%, and the Middle East & Africa–5%
The prominent player in transplant diagnostic market are bioMérieux SA (France), Becton, Dickinson and Company (US), Thermo Fisher Scientific (US), Bio-Rad Laboratories, Inc. (US)
Research Coverage
This report studies the transplant diagnostic market based on product&service, technology,application, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will enable established and entrants/smaller firms to gauge the market’s pulse, which, in turn, would help them garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.
This report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the microcatheter market.
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the microcatheter market..
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the microcatheter market.
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.
目次
1 INTRODUCTION 30
1.1 STUDY OBJECTIVES 30
1.2 MARKET DEFINITION 30
1.2.1 INCLUSIONS AND EXCLUSIONS 30
1.3 MARKET SCOPE 31
1.3.1 MARKETS COVERED 31
1.3.2 REGIONS COVERED 32
1.3.3 YEARS CONSIDERED 32
1.4 CURRENCY 32
1.5 STAKEHOLDERS 33
1.6 SUMMARY OF CHANGES 33
2 RESEARCH METHODOLOGY 35
2.1 RESEARCH DATA 35
FIGURE 1 RESEARCH DESIGN: TRANSPLANT DIAGNOSTICS MARKET 35
2.1.1 SECONDARY DATA 36
FIGURE 2 KEY DATA FROM SECONDARY SOURCES 36
2.1.2 PRIMARY DATA 37
FIGURE 3 PRIMARY SOURCES 38
2.1.2.1 Key data from primary sources 39
2.1.2.2 Insights from primary experts 40
2.1.2.3 Breakdown of primaries 40
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 41
2.2 MARKET SIZE ESTIMATION 41
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 42
FIGURE 6 TOP-DOWN APPROACH 43
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 44
FIGURE 7 DATA TRIANGULATION METHODOLOGY 45
2.3.1 METHODOLOGY-RELATED LIMITATIONS 46
2.4 RISK ASSESSMENT 47
TABLE 1 LIMITATIONS AND ASSOCIATED RISKS 47
3 EXECUTIVE SUMMARY 48
FIGURE 8 REAGENTS & CONSUMABLES TO CONTINUE TO DOMINATE TRANSPLANT DIAGNOSTICS MARKET UNTIL 2028 48
FIGURE 9 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR SEGMENT DOMINATED TRANSPLANT DIAGNOSTICS MARKET IN 2022 49
FIGURE 10 KIDNEY TRANSPLANTATION SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 50
FIGURE 11 INFECTIOUS DISEASE TESTING SEGMENT TO DOMINATE TRANSPLANT DIAGNOSTIC APPLICATIONS MARKET BY 2028 51
FIGURE 12 INDEPENDENT REFERENCE LABORATORIES TO DOMINATE MARKET DURING FORECAST PERIOD 52
FIGURE 13 REGIONAL SNAPSHOT OF TRANSPLANT DIAGNOSTICS MARKET 53
4 PREMIUM INSIGHTS 55
4.1 TRANSPLANT DIAGNOSTICS MARKET OVERVIEW 55
FIGURE 14 RISING NUMBER OF TRANSPLANTATION PROCEDURES TO DRIVE MARKET 55
4.2 TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 VS. 2028 (USD MILLION) 56
FIGURE 15 PCR-BASED MOLECULAR ASSAYS TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 56
4.3 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET SHARE, BY END USER AND COUNTRY (2022) 57
FIGURE 16 INDEPENDENT REFERENCE LABORATORIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 57
4.4 TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022 VS. 2028 (USD MILLION) 58
FIGURE 17 HEART TRANSPLANTATION SEGMENT TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 58
4.5 TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY 59
FIGURE 18 CHINA TO WITNESS HIGHEST GROWTH RATE IN TRANSPLANT DIAGNOSTICS MARKET DURING FORECAST PERIOD 59
5 MARKET OVERVIEW 60
5.1 INTRODUCTION 60
5.2 MARKET DYNAMICS 60
FIGURE 19 TRANSPLANT DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60
5.2.1 DRIVERS 61
5.2.1.1 Increasing number of transplant procedures 61
5.2.1.2 Technological advancements in transplant diagnostic procedures 61
5.2.1.3 Increasing public-private funding for target research activities 61
TABLE 2 PUBLIC-PRIVATE INVESTMENTS AND RESEARCH GRANTS FOR DEVELOPMENT OF TRANSPLANT DIAGNOSTIC PRODUCTS, 2018–2022 62
5.2.1.4 Rising prevalence of infectious diseases 63
5.2.2 RESTRAINTS 63
5.2.2.1 High procedural cost of NGS- and PCR-based diagnostic assays 63
TABLE 3 EUROPE: COST OF ASSAYS FOR MAJOR NGS/PCR-BASED GENOMIC TESTS (2021) 64
5.2.2.2 Limited reimbursement for target procedures 65
TABLE 4 US: MEDICAL REIMBURSEMENTS FOR TRANSPLANTATION PROCEDURES (2021) 65
5.2.3 OPPORTUNITIES 66
5.2.3.1 Rising adoption of cross-matching and chimerism testing during pre- & post-transplantation 66
5.2.3.2 Growing public awareness about organ donation and transplantation 66
5.2.4 CHALLENGES 66
5.2.4.1 Significant gap between number of organ donors and organs required annually 66
5.2.4.2 Procedural and technical limitations associated with donor-recipient screening 67
5.3 IMPACT OF RECESSION ON TRANSPLANT DIAGNOSTICS MARKET 67
6 TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY 68
6.1 INTRODUCTION 69
TABLE 5 TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION) 69
6.1.1 MOLECULAR ASSAY TECHNOLOGIES 69
TABLE 6 TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2020–2028 (USD MILLION) 70
TABLE 7 TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY PRODUCT & SERVICE, 2020–2028 (USD MILLION) 70
TABLE 8 TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY APPLICATION, 2020–2028 (USD MILLION) 71
TABLE 9 TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY END USER, 2020–2028 (USD MILLION) 71
TABLE 10 TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2020–2028 (USD MILLION) 72
6.1.1.1 PCR-BASED MOLECULAR ASSAYS 72
TABLE 11 TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 73
TABLE 12 TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY PRODUCT & SERVICE, 2020–2028 (USD MILLION) 73
TABLE 13 TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY APPLICATION, 2020–2028 (USD MILLION) 74
TABLE 14 TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY END USER, 2020–2028 (USD MILLION) 74
TABLE 15 TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY REGION, 2020–2028 (USD MILLION) 75
6.1.1.1.1 Sequence-specific oligonucleotide-PCR 75
6.1.1.1.1.1 Most widely adopted technique in PCR-based molecular assays market 75
TABLE 16 TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY REGION, 2020–2028 (USD MILLION) 76
6.1.1.1.2 Sequence-specific primer-PCR 76
6.1.1.1.2.1 Growing public-private investments for research activities to support market growth 76
TABLE 17 TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY REGION, 2020–2028 (USD MILLION) 77
6.1.1.1.3 Real-time PCR 77
6.1.1.1.3.1 Requires smaller sample volume compared to conventional PCR technologies 77
TABLE 18 TRANSPLANT DIAGNOSTICS MARKET FOR REAL-TIME PCR, BY REGION, 2020–2028 (USD MILLION) 78
6.1.1.1.4 Other PCR-based molecular assays 78
TABLE 19 TRANSPLANT DIAGNOSTICS MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY REGION, 2020–2028 (USD MILLION) 78
6.1.1.2 SEQUENCING-BASED MOLECULAR ASSAYS 79
TABLE 20 TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 79
TABLE 21 TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY PRODUCT & SERVICE, 2020–2028 (USD MILLION) 80
TABLE 22 TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY APPLICATION, 2020–2028 (USD MILLION) 80
TABLE 23 TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY END USER, 2020–2028 (USD MILLION) 81
TABLE 24 TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2020–2028 (USD MILLION) 81
6.1.1.2.1 Sanger sequencing 82
6.1.1.2.1.1 Growing demand for high-throughput DNA sequencers in transplant diagnostic applications to drive market 82
TABLE 25 TRANSPLANT DIAGNOSTICS MARKET FOR SANGER SEQUENCING, BY REGION, 2020–2028 (USD MILLION) 82
6.1.1.2.2 Next-generation sequencing 83
6.1.1.2.2.1 Low turnaround time and high-throughput sequencing to drive adoption of NGS 83
TABLE 26 TRANSPLANT DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2020–2028 (USD MILLION) 83
6.1.1.2.3 Other sequencing-based molecular assays 83
TABLE 27 TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2020–2028 (USD MILLION) 84
6.1.2 NON-MOLECULAR ASSAY TECHNOLOGIES 84
6.1.2.1 Replacement of non-molecular assay techniques with DNA-based techniques to hamper growth 84
TABLE 28 TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY PRODUCT & SERVICE, 2020–2028 (USD MILLION) 85
TABLE 29 TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY APPLICATION, 2020–2028 (USD MILLION) 85
TABLE 30 TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY END USER, 2020–2028 (USD MILLION) 86
TABLE 31 TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2020–2028 (USD MILLION) 86
7 TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 87
7.1 INTRODUCTION 88
TABLE 32 TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2028 (USD MILLION) 88
7.1.1 REAGENTS & CONSUMABLES 88
7.1.1.1 Largest and fastest-growing segment of transplant diagnostics market 88
TABLE 33 TRANSPLANT DIAGNOSTICS MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2020–2028 (USD MILLION) 89
7.1.2 INSTRUMENTS 89
7.1.2.1 Increasing public-private investments to drive market 89
TABLE 34 TRANSPLANT DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2020–2028 (USD MILLION) 90
7.1.3 SOFTWARE & SERVICES 90
7.1.3.1 Growing automation & digitalization of diagnostic laboratory procedures to support market growth 90
TABLE 35 TRANSPLANT DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2020–2028 (USD MILLION) 91
8 TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 92
8.1 INTRODUCTION 93
TABLE 36 TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 93
8.1.1 DIAGNOSTIC APPLICATIONS 93
TABLE 37 TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2028 (USD MILLION) 94
TABLE 38 TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2020–2028 (USD MILLION) 94
8.1.1.1 Pre-transplantation diagnostics 94
TABLE 39 PRE-TRANSPLANTATION DIAGNOSTICS MARKET, BY TYPE, 2020–2028 (USD MILLION) 95
TABLE 40 PRE-TRANSPLANTATION DIAGNOSTICS MARKET, BY REGION, 2020–2028 (USD MILLION) 95
8.1.1.1.1 Infectious disease testing 96
8.1.1.1.1.1 Growing adoption of advanced molecular techniques for pathogen detection to drive market 96
TABLE 41 INFECTIOUS DISEASE TESTING MARKET, BY REGION, 2020–2028 (USD MILLION) 96
8.1.1.1.2 Histocompatibility testing 96
8.1.1.1.2.1 Technological advancements and growing R&D activities to propel market 96
TABLE 42 HISTOCOMPATIBILITY TESTING MARKET, BY REGION, 2020–2028 (USD MILLION) 97
8.1.1.1.3 Blood profiling 97
8.1.1.1.3.1 Growing availability of molecular assay products to support market growth 97
TABLE 43 BLOOD PROFILING MARKET, BY REGION, 2020–2028 (USD MILLION) 98
8.1.1.2 Post-transplantation diagnostics 98
8.1.1.2.1 Greater risk of disorders and infections post-transplantation makes diagnostics necessary step 98
TABLE 44 POST-TRANSPLANTATION DIAGNOSTICS MARKET, BY REGION, 2020–2028 (USD MILLION) 98
8.1.2 RESEARCH APPLICATIONS 99
8.1.2.1 Growing funding for research to drive market 99
TABLE 45 TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020–2028 (USD MILLION) 99
9 TRANSPLANT DIAGNOSTICS MARKET, BY END USER 100
9.1 INTRODUCTION 101
TABLE 46 TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2020–2028 (USD MILLION) 101
9.1.1 INDEPENDENT REFERENCE LABORATORIES 101
9.1.1.1 Rising consolidation of diagnostic laboratories to drive market 101
TABLE 47 TRANSPLANT DIAGNOSTICS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY REGION, 2020–2028 (USD MILLION) 102
9.1.2 HOSPITALS & TRANSPLANT CENTERS 102
9.1.2.1 Growing purchasing power of hospitals & transplant centers to support market growth 102
TABLE 48 TRANSPLANT DIAGNOSTICS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2020–2028 (USD MILLION) 103
9.1.3 RESEARCH LABORATORIES & ACADEMIC INSTITUTES 103
9.1.3.1 Increasing industry-academia collaborations in genomics-based transplant diagnostic research to drive market 103
TABLE 49 TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2020–2028 (USD MILLION) 104
10 TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE 105
10.1 INTRODUCTION 106
TABLE 50 TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020–2028 (USD MILLION) 106
10.1.1 SOLID ORGAN TRANSPLANTATION 106
TABLE 51 SOLID ORGAN TRANSPLANTATION MARKET, BY TYPE, 2020–2028 (USD MILLION) 107
TABLE 52 SOLID ORGAN TRANSPLANTATION MARKET, BY REGION, 2020–2028 (USD MILLION) 107
10.1.1.1 Kidney transplantation 108
10.1.1.1.1 Rising prevalence of kidney diseases to drive market 108
FIGURE 20 NUMBER OF KIDNEY TRANSPLANTATION PROCEDURES IN MAJOR MARKETS, 2022 VS. 2028 108
TABLE 53 KIDNEY TRANSPLANTATION MARKET, BY REGION, 2020–2028 (USD MILLION) 109
10.1.1.2 Liver transplantation 109
10.1.1.2.1 Growing patient population with chronic liver diseases and increasing procedural volume to drive market 109
FIGURE 21 NUMBER OF LIVER TRANSPLANTATION PROCEDURES IN MAJOR MARKETS, 2022 VS. 2028 110
TABLE 54 LIVER TRANSPLANTATION MARKET, BY REGION, 2020–2028 (USD MILLION) 110
10.1.1.3 Lung transplantation 110
10.1.1.3.1 Rising prevalence of chronic lung diseases to drive market 110
FIGURE 22 NUMBER OF LUNG TRANSPLANTATION PROCEDURES IN MAJOR MARKETS, 2022 VS. 2028 111
TABLE 55 LUNG TRANSPLANTATION MARKET, BY REGION, 2020–2028 (USD MILLION) 111
10.1.1.4 Heart transplantation 111
10.1.1.4.1 Increasing prevalence of chronic cardiac diseases to propel market 111
FIGURE 23 NUMBER OF HEART TRANSPLANTATION PROCEDURES IN MAJOR MARKETS, 2022 VS. 2028 112
TABLE 56 HEART TRANSPLANTATION MARKET, BY REGION, 2020–2028 (USD MILLION) 112
10.1.1.5 Pancreas transplantation 113
10.1.1.5.1 Procedural complexity and risk of surgical complications to restrain growth 113
FIGURE 24 NUMBER OF PANCREAS TRANSPLANTATION PROCEDURES IN MAJOR MARKETS, 2022 VS. 2028 113
TABLE 57 PANCREAS TRANSPLANTATION MARKET, BY REGION, 2020–2028 (USD MILLION) 114
10.1.1.6 Other organ transplantation 114
TABLE 58 OTHER ORGAN TRANSPLANTATION MARKET, BY REGION, 2020–2028 (USD MILLION) 114
10.1.2 STEM CELL TRANSPLANTATION 115
10.1.2.1 Rising procedural volume and growing research activities to drive market 115
TABLE 59 STEM CELL TRANSPLANTATION MARKET, BY REGION, 2020–2028 (USD MILLION) 115
10.1.3 SOFT TISSUE TRANSPLANTATION 116
10.1.3.1 Technological advancements and rising prevalence of target diseases to drive market 116
TABLE 60 SOFT TISSUE TRANSPLANTATION MARKET, BY REGION, 2020–2028 (USD MILLION) 116
10.1.4 BONE MARROW TRANSPLANTATION 116
10.1.4.1 Dearth of well-trained surgeons to perform bone marrow transplantation to hinder growth 116
TABLE 61 BONE MARROW TRANSPLANTATION MARKET, BY REGION, 2020–2028 (USD MILLION) 117
11 TRANSPLANT DIAGNOSTICS MARKET, BY REGION 118
11.1 INTRODUCTION 119
TABLE 62 TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020–2028 (USD MILLION) 119
11.1.1 NORTH AMERICA 119
FIGURE 25 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET SNAPSHOT 120
TABLE 63 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2020–2028 (USD MILLION) 121
TABLE 64 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION) 121
TABLE 65 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 122
TABLE 66 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 122
TABLE 67 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2028 (USD MILLION) 123
TABLE 68 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 123
TABLE 69 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020–2028 (USD MILLION) 124
TABLE 70 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2020–2028 (USD MILLION) 124
11.1.1.1 US 125
11.1.1.1.1 Technological advancements in transplant diagnostics to drive market 125
FIGURE 26 US: SOLID ORGAN TRANSPLANTATION PROCEDURES, 2019–2021 125
TABLE 71 US: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION) 126
TABLE 72 US: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 126
TABLE 73 US: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 127
11.1.1.2 Canada 127
11.1.1.2.1 Growing availability of transplant diagnostic products to support market growth 127
FIGURE 27 CANADA: SOLID ORGAN TRANSPLANTATION PROCEDURES, 2019–2021 127
TABLE 74 CANADA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION) 128
TABLE 75 CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 128
TABLE 76 CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 129
11.1.2 EUROPE 129
TABLE 77 EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2020–2028 (USD MILLION) 130
TABLE 78 EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION) 130
TABLE 79 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 131
TABLE 80 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 131
TABLE 81 EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2028 (USD MILLION) 132
TABLE 82 EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 132
TABLE 83 EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020–2028 (USD MILLION) 133
TABLE 84 EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2020–2028 (USD MILLION) 133
11.1.2.1 GERMANY 134
11.1.2.1.1 Largest market for transplant diagnostics in Europe 134
TABLE 85 GERMANY: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION) 134
TABLE 86 GERMANY: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 135
TABLE 87 GERMANY: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 135
11.1.2.2 UK 136
11.1.2.2.1 Rising number of transplantation procedures to drive market 136
TABLE 88 UK: ORGAN TRANSPLANTATION PROCEDURES, 2019 VS. 2021 136
TABLE 89 UK: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION) 136
TABLE 90 UK: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 137
TABLE 91 UK: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 137
11.1.2.3 France 138
11.1.2.3.1 Increased adoption of molecular diagnostic techniques for donor-recipient compatibility testing to propel market 138
TABLE 92 FRANCE: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION) 138
TABLE 93 FRANCE: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 139
TABLE 94 FRANCE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 139
11.1.2.4 Spain 140
11.1.2.4.1 Rising number of solid organ transplantation procedures to drive market 140
TABLE 95 SPAIN: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION) 140
TABLE 96 SPAIN: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 141
TABLE 97 SPAIN: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 141
11.1.2.5 Italy 142
11.1.2.5.1 Sluggish growth in healthcare sector to restrain market growth 142
TABLE 98 ITALY: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION) 142
TABLE 99 ITALY: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 143
TABLE 100 ITALY: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 143
11.1.2.6 Rest of Europe 144
TABLE 101 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION) 144
TABLE 102 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 145
TABLE 103 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 145
11.1.3 ASIA PACIFIC 145
FIGURE 28 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET SNAPSHOT 146
TABLE 104 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2020–2028 (USD MILLION) 147
TABLE 105 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION) 147
TABLE 106 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 148
TABLE 107 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 148
TABLE 108 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2028 (USD MILLION) 149
TABLE 109 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 149
TABLE 110 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020–2028 (USD MILLION) 150
TABLE 111 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2020–2028 (USD MILLION) 150
11.1.3.1 China 151
11.1.3.1.1 Improvements in healthcare infrastructure to support market growth 151
TABLE 112 CHINA: ORGAN TRANSPLANTATION PROCEDURES, 2019 VS. 2021 151
TABLE 113 CHINA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION) 151
TABLE 114 CHINA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 152
TABLE 115 CHINA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 152
11.1.3.2 India 153
11.1.3.2.1 Increasing number of transplantation procedures to drive market 153
TABLE 116 INDIA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION) 153
TABLE 117 INDIA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 153
TABLE 118 INDIA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 154
11.1.3.3 Japan 154
11.1.3.3.1 Rising prevalence of chronic diseases to support market growth 154
FIGURE 29 JAPAN: SOLID ORGAN TRANSPLANTATION PROCEDURES, 2019–2021 154
TABLE 119 JAPAN: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION) 155
TABLE 120 JAPAN: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 155
TABLE 121 JAPAN: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 156
11.1.3.4 Australia 156
11.1.3.4.1 Rising number of solid organ transplantation procedures to drive market 156
TABLE 122 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION) 156
TABLE 123 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 157
TABLE 124 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 157
11.1.3.5 South Korea 158
11.1.3.5.1 Government initiatives to introduce medical coverage for transplantation to drive market 158
TABLE 125 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION) 158
TABLE 126 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 159
TABLE 127 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 159
11.1.3.6 Rest of Asia Pacific 159
TABLE 128 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION) 160
TABLE 129 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 160
TABLE 130 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 161
11.1.4 LATIN AMERICA 161
TABLE 131 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2020–2028 (USD MILLION) 162
TABLE 132 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION) 162
TABLE 133 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 163
TABLE 134 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 163
TABLE 135 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2028 (USD MILLION) 164
TABLE 136 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 164
TABLE 137 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020–2028 (USD MILLION) 165
TABLE 138 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2020–2028 (USD MILLION) 165
11.1.4.1 Brazil 166
11.1.4.1.1 Rising investments by leading transplant diagnostic manufacturers to favor market growth 166
TABLE 139 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION) 166
TABLE 140 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 167
TABLE 141 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 167
11.1.4.2 Mexico 168
11.1.4.2.1 Rising medical tourism to support market growth 168
TABLE 142 MEXICO: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION) 168
TABLE 143 MEXICO: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 169
TABLE 144 MEXICO: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 169
11.1.4.3 Rest of Latin America 170
TABLE 145 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION) 170
TABLE 146 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 170
TABLE 147 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 171
11.1.5 MIDDLE EAST & AFRICA 171
11.1.5.1 Developing healthcare infrastructure to favor market growth 171
TABLE 148 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION) 172
TABLE 149 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 172
TABLE 150 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION) 173
TABLE 151 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2028 (USD MILLION) 173
TABLE 152 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 174
TABLE 153 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020–2028 (USD MILLION) 174
TABLE 154 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2020–2028 (USD MILLION) 175
12 COMPETITIVE LANDSCAPE 176
12.1 INTRODUCTION 176
12.2 STRATEGIES ADOPTED BY KEY PLAYERS 176
FIGURE 30 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN TRANSPLANT DIAGNOSTICS MARKET 177
12.3 MARKET SHARE ANALYSIS 178
FIGURE 31 TRANSPLANT DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2021 178
12.4 COMPETITIVE SCENARIO 179
12.4.1 PRODUCT LAUNCHES AND APPROVALS 179
12.4.2 DEALS 179
12.5 COMPETITIVE LEADERSHIP MAPPING 180
12.5.1 STARS 181
12.5.2 EMERGING LEADERS 181
12.5.3 PERVASIVE PLAYERS 181
12.5.4 PARTICIPANTS 181
FIGURE 32 TRANSPLANT DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021 182
13 COMPANY PROFILES 183
13.1 KEY PLAYERS 183
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 BIO-RAD LABORATORIES 183
TABLE 155 BIO-RAD LABORATORIES: COMPANY OVERVIEW (2021) 183
FIGURE 33 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2021) 184
13.1.2 F. HOFFMANN-LA ROCHE LTD. 188
TABLE 156 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW (2021) 188
FIGURE 34 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021) 189
13.1.3 QIAGEN NV 192
TABLE 157 QIAGEN NV: COMPANY OVERVIEW (2021) 192
FIGURE 35 QIAGEN NV: COMPANY SNAPSHOT (2021) 193
13.1.4 BECTON, DICKINSON AND COMPANY 199
TABLE 158 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW (2021) 199
FIGURE 36 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021) 200
13.1.5 BIOFORTUNA 202
13.1.6 BIOMÉRIEUX SA 203
TABLE 159 BIOMÉRIEUX SA: COMPANY OVERVIEW (2021) 203
FIGURE 37 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2021) 204
13.1.7 CAREDX 206
TABLE 160 CAREDX: COMPANY OVERVIEW (2021) 206
FIGURE 38 CAREDX: COMPANY SNAPSHOT (2021) 207
13.1.8 GENDX 210
TABLE 161 GENDX: COMPANY OVERVIEW (2021) 210
13.1.9 HOLOGIC, INC. 212
TABLE 162 HOLOGIC, INC.: COMPANY OVERVIEW (2021) 212
FIGURE 39 HOLOGIC, INC.: COMPANY SNAPSHOT (2021) 213
13.1.10 ILLUMINA, INC. 215
TABLE 163 ILLUMINA, INC.: COMPANY OVERVIEW (2021) 215
FIGURE 40 ILLUMINA, INC.: COMPANY SNAPSHOT (2021) 216
13.1.11 IMMUCOR, INC. 219
TABLE 164 IMMUCOR, INC.: COMPANY OVERVIEW (2021) 219
FIGURE 41 IMMUCOR, INC.: COMPANY SNAPSHOT (2021) 220
13.1.12 LUMINEX CORPORATION 224
TABLE 165 LUMINEX CORPORATION: COMPANY OVERVIEW (2021) 224
FIGURE 42 LUMINEX CORPORATION: COMPANY SNAPSHOT (2021) 225
13.1.13 MERCK KGAA 227
TABLE 166 MERCK KGAA: COMPANY OVERVIEW (2021) 227
FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT (2021) 228
13.1.14 OMIXON 229
TABLE 167 OMIXON: COMPANY OVERVIEW (2021) 229
13.1.15 THERMO FISHER SCIENTIFIC 231
TABLE 168 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW (2021) 231
FIGURE 44 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2021) 232
13.2 OTHER PLAYERS 235
13.2.1 ALPHABIOTECH LIMITED 235
13.2.2 BAG DIAGNOSTICS GMBH 236
13.2.3 HANSA BIOPHARMA AB 237
13.2.4 HISTOGENETICS LLC 237
13.2.5 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 238
13.2.6 TBG DIAGNOSTICS LIMITED 239
13.2.7 TAKARA BIO INC. 240
13.2.8 INNO-TRAIN DIAGNOSTIK GMBH 241
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX 242
14.1 DISCUSSION GUIDE 242
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 257
14.3 CUSTOMIZATION OPTIONS 259
14.4 RELATED REPORTS 259
14.5 AUTHOR DETAILS 260